Extracellular Matrix in the Tumor Microenvironment and Its Impact on Cancer Therapy

被引:684
作者
Henke, Erik [1 ]
Nandigama, Rajender [1 ]
Ergun, Suleyman [1 ]
机构
[1] Univ Wurzburg, Inst Anat & Cell Biol, Dept Med, Wurzburg, Germany
关键词
extracellular matrix; cancer therapy; drug transport; immunotherapy; chemotherapy (CH); radiotherapy; tumor microenvironment; ECM; EPITHELIAL-MESENCHYMAL TRANSITION; CARCINOMA-ASSOCIATED FIBROBLASTS; COLLAGEN TYPE-I; TRANSCAPILLARY PRESSURE-GRADIENT; RECOMBINANT HUMAN HYALURONIDASE; CHRONIC MYELOGENOUS LEUKEMIA; RADIATION-INDUCED INCREASE; T-CELL INFILTRATION; BREAST-CANCER; LYSYL OXIDASE;
D O I
10.3389/fmolb.2019.00160
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Solid tumors are complex organ-like structures that consist not only of tumor cells but also of vasculature, extracellular matrix (ECM), stromal, and immune cells. Often, this tumor microenvironment (TME) comprises the larger part of the overall tumor mass. Like the other components of the TME, the ECM in solid tumors differs significantly from that in normal organs. Intratumoral signaling, transport mechanisms, metabolisms, oxygenation, and immunogenicity are strongly affected if not controlled by the ECM. Exerting this regulatory control, the ECM does not only influence malignancy and growth of the tumor but also its response toward therapy. Understanding the particularities of the ECM in solid tumor is necessary to develop approaches to interfere with its negative effect. In this review, we will also highlight the current understanding of the physical, cellular, and molecular mechanisms by which the pathological tumor ECM affects the efficiency of radio-, chemo-, and immunotherapy. Finally, we will discuss the various strategies to target and modify the tumor ECM and how they could be utilized to improve response to therapy.
引用
收藏
页数:24
相关论文
共 315 条
  • [1] Adams S, 2018, ANN ONCOL, V30, P405, DOI DOI 10.1093/annonc/mdy517
  • [2] [Anonymous], 2010, CANCER RES
  • [3] [Anonymous], 2018, GASTROENTEROLOGY
  • [4] [Anonymous], 2012, J CLIN INVEST
  • [5] [Anonymous], 2013, AM J PATHOL, DOI DOI 10.1016/j.ajpath.2013.06.026
  • [6] [Anonymous], 2011, BIOMED OPT EXPRESS
  • [7] [Anonymous], 2002, CLIN CANCER RES
  • [8] [Anonymous], 2018, ZHONG NAN DA XUE XUE
  • [9] [Anonymous], 2012, P NATL ACAD SCI USA
  • [10] [Anonymous], 2017, J THORAC ONCOL